Matsumoto K - Search Results

1

Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study.

Yamamoto T, Umegae S, Matsumoto K. Yamamoto T, et al. Among authors: matsumoto k. Inflamm Bowel Dis. 2010 Nov;16(11):1905-11. doi: 10.1002/ibd.21260. Inflamm Bowel Dis. 2010. PMID: 20310015

2

Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.

Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Yamamoto T, et al. Among authors: matsumoto k. Int J Colorectal Dis. 2014 Apr;29(4):485-91. doi: 10.1007/s00384-013-1817-3. Epub 2013 Dec 17. Int J Colorectal Dis. 2014. PMID: 24343276

3

Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis.

Yamamoto T, Umegae S, Matsumoto K. Yamamoto T, et al. Among authors: matsumoto k. J Crohns Colitis. 2012 Aug;6(7):750-5. doi: 10.1016/j.crohns.2011.12.009. Epub 2012 Jan 12. J Crohns Colitis. 2012. PMID: 22398094

4

Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis.

Yamamoto T, Umegae S, Matsumoto K. Yamamoto T, et al. Among authors: matsumoto k. World J Gastroenterol. 2006 Jan 28;12(4):520-5. doi: 10.3748/wjg.v12.i4.520. World J Gastroenterol. 2006. PMID: 16489663 Free PMC article. Review.

5

Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings.

Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Yamamoto T, et al. Among authors: matsumoto k. Inflamm Bowel Dis. 2006 Aug;12(8):719-26. doi: 10.1097/00054725-200608000-00008. Inflamm Bowel Dis. 2006. PMID: 16917227

6

Enteral nutrition for the maintenance of remission in Crohn's disease: a systematic review.

Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Yamamoto T, et al. Among authors: matsumoto k. Eur J Gastroenterol Hepatol. 2010 Jan;22(1):1-8. doi: 10.1097/MEG.0b013e32832c788c. Eur J Gastroenterol Hepatol. 2010. PMID: 19707151 Review.

7

Faecal biomarkers for screening small bowel inflammation in patients with Crohn's disease: a prospective study.

Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Shimoyama T, et al. Among authors: matsumoto k. Therap Adv Gastroenterol. 2017 Aug;10(8):577-587. doi: 10.1177/1756283X17717683. Epub 2017 Jul 4. Therap Adv Gastroenterol. 2017. PMID: 28835772 Free PMC article.

8

Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing.

Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Yamamoto T, et al. Among authors: matsumoto k. Clin Transl Gastroenterol. 2018 Feb 20;9(3):136. doi: 10.1038/s41424-018-0006-7. Clin Transl Gastroenterol. 2018. PMID: 29491393 Free PMC article.

9

Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study.

Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Shimoyama T, et al. Among authors: matsumoto k. BMC Gastroenterol. 2018 Aug 1;18(1):120. doi: 10.1186/s12876-018-0853-4. BMC Gastroenterol. 2018. PMID: 30068300 Free PMC article.

10

Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn's disease: a long-term prospective study.

Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Yamamoto T, et al. Among authors: matsumoto k. Therap Adv Gastroenterol. 2016 Sep;9(5):664-70. doi: 10.1177/1756283X16646562. Epub 2016 May 1. Therap Adv Gastroenterol. 2016. PMID: 27582878 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results